作为股市风向标，私募基金的调研动向往往揭示资金偏好，备受行业关注。随着股市持续回暖，私募基 金近期开启新一轮密集调研。 私募排排网最新数据显示，6月共有751家私募证券管理人调研387家A股上市公司，合计达1769次。其 中，电子、医药生物两大行业备受私募青睐，合计被调研541次，占比逾三成。迈威生物当月获得私募 扎堆调研51次，成为机构眼中的"香饽饽"，这也与当下创新药的火爆紧密相连。 值得注意的是，私募机构对后市普遍持积极乐观态度。有私募分析，随着"反内卷"政策逐步深化，上市 公司的产能周期已临近尾声，这意味着盈利下行周期即将终结。 电子和医药生物受青睐 酷暑仍挡不住私募机构调研积极性。私募排排网最新数据显示，6月有751家私募证券管理人参与A股上 市公司调研，覆盖28个申万一级行业中的387只个股。 从调研热度来看，6月共有46只个股获得私募机构的高度关注，调研频次均不少于10次。具体来看，32 只个股被调研10～19次，14只个股调研频次不少于20次。其中，迈威生物、海光信息、中科曙光位列被 机构调研的次数前三。 值得注意的是，迈威生物6月获得私募调研51次，成为最受私募青睐的个股，该股属于医药生物行 ...

日前，谷歌旗下抗衰老公司 Calico Life Sciences 宣布 与 迈威生物 （Mabwell） 达成一项总价 近6 亿美 元 的生物制药交易，以获取针对 白介素-11 （IL-11） 的研究性疗法权益，其中包括一种用于治疗年龄相 关疾病的临床阶段单克隆抗体 9MW3811 。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 据悉，迈威生物已在临床前研究中探索了 9MW3811 在年龄相关疾病领域的治疗潜力，已在中国及澳大利 亚完成了 1 期临床研究 ，显示出对 特发性肺纤维化的治疗潜力 ，并在美国获批开展 1 期临床研究。 根据许可协议，迈威生物独家许可 Calico 在除大中华区以外所有区域内独家开发、生产和商业化 9MW3811 的权利。 Calico 将向迈威生物支付一次性不可退还的首付款 2500 万美元 ，此外，迈威生物 还可额外获得合计最高达 5.71 亿美元 的近端、开发、注册及商业化里程碑付款 ，以及按许可产品净销售 额计算的阶梯式特许权使用费。 Calico 由谷歌母公司 Alphabet 和行业巨 头 Arthur Levinson 博士共同创立，该公司旨在进一步了解衰老 的生物学原理 ...

证券研究报告 东吴证券晨会纪要 东吴证券晨会纪要 2025-07-01 [Table_MacroStrategy] 宏观量化经济指数周报 20250630：内需延续结构分化，外需保持总量平 稳 货币政策对"资金空转"的关注度依然较高，仍然偏重提高资金使用效率 海外周报 20250629：特朗普《大美丽法案》开始闯关参议院 核心观点：本周以伊冲突与贸易谈判局势缓和令美股大涨，美联储理事 Waller 与 Bowman 的鸽派发言与经济数据走弱令美债利率大幅走低，10 年期美债利率下至 4.277%，美元指数下行至 97.4；黄金与原油价格在避 险情绪大幅降温的情况下分别下跌 2.79%和 12.56%。在美国部分批发商 "抢进口"行为告一段落后，本月分析师大幅上修 Q2 美国 GDP 增速预 期，同时维持美联储 Q3 首次降息，全年降息 2 次的预期不变。向前看， 特朗普《大美丽法案》本周已于参议院进入最终审议阶段，在于 8 月中 下旬来临的 X Date 前提高债务上限的需要或令法案最终通过的 "Deadline"为 7 月 31 日。 风险提示：特朗普政策超预期；美联储降息 幅度过大引发通胀反弹甚至失控；美 ...

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The report highlights that Maiwei Biotech has achieved two licensing agreements, which will enhance cash flow and may indicate a turning point in its operations [5][14] - The pharmaceutical and biotechnology sector has seen a 1.6% increase this week, underperforming the CSI 300 index by 0.35 percentage points, ranking 23rd among 31 sub-industries [7][20] - The report emphasizes the accelerating trend in licensing out Chinese innovative drugs, with the total licensing amount exceeding 51.9 billion USD in 2024, marking a 27.4% year-on-year increase [18][19] Summary by Sections Weekly Insights - Maiwei Biotech's recent licensing agreements include a 25 million USD upfront payment and potential milestone payments totaling up to 571 million USD with CALICO Life Sciences for IL-11 targeted therapy, and a 3.8 billion CNY upfront payment with Qilu Pharmaceutical for 8MW0511 [5][14][15] - The report notes that the cash flow issues for Maiwei Biotech are expected to be significantly alleviated due to these agreements, with further business development opportunities anticipated [6] Subsector Performance - The pharmaceutical and biotechnology sector increased by 1.6% this week, with all sub-sectors showing growth. The hospital sector had the highest increase at 3.92% [7][24] - The report identifies key investment opportunities in various subsectors, including innovative drugs, medical devices, and medical consumables, with specific companies recommended for investment [8][28][29][30] Recommended and Benefiting Stocks - Recommended stocks include Innovent Biologics, Hengrui Medicine, and medical device companies such as YK Medical and Mindray Medical [8][31] - Benefiting stocks in the innovative drug sector include companies like Zai Lab, BeiGene, and others in both A-shares and H-shares [8][34][35] Market Trends - The report indicates that the innovative drug sector is expected to continue its upward trajectory, driven by strong clinical data and increased business development activities [28] - The medical device sector is projected to benefit from government policies promoting equipment upgrades, with a significant increase in procurement expected in the second quarter of 2025 [29][30]

Core Viewpoint - The company has made significant licensing agreements that enhance cash flow and pave the way for future commercialization of its products, including the injection of Agonist α and IL-11 targeted therapy drugs [1][2]. Group 1: Financial Impact - The total upfront payments from the two transactions amount to over 560 million RMB (3.8 billion + 250 million), which alleviates the company's financial pressure, with an estimated cash balance of approximately 1.23 billion RMB in 2024 [2]. - The agreements include a maximum total transaction amount of 500 million RMB and a tiered royalty percentage based on net sales, which will further support the company's financial health [1]. Group 2: Technological Validation - The two business development targets (8MW0511 and 9MW3811) are self-developed by the company, validating its long-acting fusion protein technology and LALA modification technology's competitive edge [3][4]. - 8MW0511 is the first approved long-acting G-CSF in China, utilizing albumin fusion technology to avoid the toxicity risks associated with PEG modification, demonstrating low immunogenicity and high production efficiency [3]. - 9MW3811 employs LALA modification technology to reduce potential toxicity risks and has shown a long half-life in clinical data, indicating significant market potential in diseases like pulmonary fibrosis [4]. Group 3: Core Assets and Future Potential - The company possesses a proprietary technology platform in the ADC field, with multiple targets and new payloads, showing promising clinical data in combination therapies [5]. - In the TCE field, the company is optimizing target selection and spatial design to reduce cytokine release syndrome (CRS) risks, with preclinical models demonstrating significant tumor suppression effects [5]. - Collaborations with AI companies are being utilized to accelerate target screening and evaluation, enhancing the company's research capabilities [5]. Group 4: Revenue Forecast - The company projects revenues of 851 million, 1.514 billion, and 2.08 billion RMB for 2025-2027, with year-on-year growth rates of 325.97%, 77.91%, and 37.38% respectively [6]. - The expected net profit for the same period is projected to be -591 million, -280 million, and 104 million RMB, with growth rates of 43.4%, 52.65%, and 137.14% respectively [6].

● 本报记者 傅苏颖 近期，国内创新药产业海外授权密集落地，迈威生物等药企接连达成海外授权合作。业内人士认为，近 年来，多项创新药相关政策大力支持医药企业创新，同时随着跨国公司专利悬崖密集到来，专利药销售 出现下滑压力，中国创新药获青睐。今年以来，在研发创新和国际化的助力之下，国内创新药行业高景 气可期。 海外授权密集落地 我国创新药进入收获期 6月27日，国家药品监督管理局官网披露，近日，国家药监局批准信达生物申报的1类创新药玛仕度肽注 射液（商品名：信尔美）上市。该药品上市为患者提供了新的治疗选择。在此前的5月29日，国家药监 局集中批准11款创新药上市，其中多款为1类创新药。 国联民生证券认为，创新药或将逐步进入兑现期。2025年预计是国内创新药授权出海的重要年份，自 2018年国家药品集采政策实施以后，国内企业纷纷开始从仿制药向创新药转型，至今7年时间，已陆续 进入兑现期。部分先驱创新药企业有望实现盈亏平衡，利润端转正。 例如恒瑞医药坚持科技创新和国际化双轮驱动发展战略，业绩稳健增长。恒瑞医药始终锚定创新研发， 累计研发投入达460亿元，目前在全球设立了14个研发中心，全球研发团队超5500人。已在国 ...

Core Viewpoint - Recently, Maiwei Biotech announced two significant licensing agreements, potentially exceeding a total value of 4.7 billion RMB, which could enhance the company's operational strength and support its long-term development strategy [2][3][5]. Group 1: Licensing Agreements - Maiwei Biotech signed an exclusive licensing agreement with CALICO, a subsidiary of Alphabet, for the IL-11 targeted therapy, which includes the product 9MW3811. The agreement allows CALICO to develop, produce, and commercialize the product outside of China [3][4]. - The agreement with CALICO includes an upfront payment of 25 million USD (approximately 250 million RMB) and potential milestone payments totaling up to 571 million USD (approximately 4.095 billion RMB), along with royalties based on net sales [3][4]. - The second agreement with Qilu Pharmaceutical involves the product 8MW0511, which is an injectable drug for treating febrile neutropenia in cancer patients. This agreement includes an upfront payment of 3.8 billion RMB and potential sales milestone payments, as well as royalties based on net sales [4][6]. Group 2: Company Background and Financials - Founded in 2017, Maiwei Biotech focuses on the research, production, and sales of innovative drugs and biosimilars, primarily in oncology and other therapeutic areas [3][6]. - As of the end of 2024, the company has three products on the market but has not yet achieved profitability, with accumulated losses [3][6]. - In Q1 2025, the company reported revenue of 44.79 million RMB, a year-on-year decline of 33.7%, and a net loss of 292 million RMB, indicating an increase in losses due to high R&D expenditures [7]. - The company is preparing for an IPO on the Hong Kong Stock Exchange to alleviate financial pressures and enhance its international presence [7].

Core Viewpoint - The recent large-scale business development (BD) transactions in the biopharmaceutical industry have sparked market enthusiasm and investor anticipation for future significant deals [1][2]. Group 1: BD Transactions - Maiwei Biotech (688062.SH) disclosed two BD transactions on June 27, with a total upfront payment of 559 million yuan and a potential total transaction value of 4.6 billion yuan [1]. - The first transaction involves an exclusive licensing agreement with Calico Life Sciences for the IL-11 targeted therapy 9MW3811, which includes an upfront payment of $25 million (approximately 179 million yuan) and potential milestone payments of up to $571 million (approximately 4.1 billion yuan) [3][4]. - The second transaction is a licensing agreement with Qilu Pharmaceutical for the injection of Agrelistat α, with a total transaction value of up to 500 million yuan, including an upfront payment of 380 million yuan [5][6]. Group 2: Financial Performance and Strategy - Maiwei Biotech aims to achieve profitability and balance its financials, emphasizing the importance of increasing commercial sales revenue and advancing its innovative products for both domestic and international markets [3][8]. - The company reported revenues of 27.73 million yuan in 2022, 128 million yuan in 2023, and 200 million yuan in 2024, with significant year-on-year growth rates [7]. - Despite revenue growth, the company faced cumulative losses of 3.053 billion yuan due to high R&D expenditures, leading to a cash flow challenge with 1.073 billion yuan in short-term loans [8]. Group 3: Market Outlook and Industry Trends - The BD transactions are seen as a crucial cash flow supplement for innovative drug companies, with industry analysts noting a trend of leading companies moving towards profitability [9]. - The international capital market is beginning to reassess the value of Chinese innovative drugs, supported by favorable policies and a more diversified payment system for market expansion [10]. - The successful execution of BD transactions and the advancement of clinical pipelines will be critical for Maiwei Biotech's long-term positioning in the global value chain of innovative drugs [10].

迈威生物：与CALICO拟就IL-11靶向治疗（包括9MW3811）签署独家许可协议 智通财经6月26日电，迈威生物(688062.SH)公告称，公司与CALICO拟就IL-11靶向治疗（包括 9MW3811）签署《独家许可协议》。根据许可协议，迈威生物独家许可CALICO在除大中华区（中国 大陆、香港、澳门和台湾）以外的所有区域内独家开发、生产和商业化许可产品的权利。迈威生物可获 得首付款及里程碑付款，以及按许可产品净销售额计算的阶梯式特许权使用费。9MW3811是一款公司 自主研发的靶向人白介素-11（IL-11）的人源化单克隆抗体，可高效阻断IL-11下游信号通路的活化，抑 制IL-11诱导的病理生理功能，从而达到对纤维化和肿瘤的治疗效果。9MW3811已在中、澳、美三地获 批开展临床试验，目前已完成中、澳I期临床研究。CALICO是一家由Alphabet Inc.与 Arthur D. Levinson 创立的研发公司，其使命是利用先进的技术和模型系统来增加我们对控制人类衰老的生物学机制的理 解。CALICO将向迈威生物支付一次性不可退还的首付款2,500万美元，此外，迈威生物还可额外获得合 计最高达 ...